Skip to main content
Equibles

4506 · Sumitomo Pharma Co., Ltd. · Financials

Use 4506 with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research 4506.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,934 JPY -4.5 (-0.23%) At close · Nov 11
Rebalance outlook locked
Market Cap
867.58B JPY
Shares
448.59M
Volume · Nov 11 2.47M Avg daily vol (3M) 3.97M

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
453.29B +13.7%
FY2026 Revenue FY2022–FY2026
Net Income
106.87B +352.2%
FY2026 Net Income FY2022–FY2026
Gross Margin
56.67% -4.9pp
FY2026 Gross Margin FY2022–FY2026
Operating Margin
23.68% +16.5pp
FY2026 Operating Margin FY2022–FY2026
Operating Cash Flow
71.72B +334.6%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item FY2026 FY2025 FY2024 FY2023 FY2022
JPY 453.29B 398.83B 314.56B 555.54B 560.04B
JPY 196.4B 153.44B 126.58B 178.92B 157.13B
JPY 256.89B 245.4B 187.98B 376.63B 402.91B
JPY 107.34B 28.8B -354.86B -76.98B 60.23B
JPY 100.34B 17.61B -323.11B -47.92B 82.96B
JPY -6.52B -6.02B -8.19B 48.79B 42.36B
JPY 106.87B 23.63B -314.97B -74.51B 56.41B
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 25.05B in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.